Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Rocket Pharmaceuticals (RCKT) over the last 1 years, with Dec 2018 value amounting to $457,000.

  • Rocket Pharmaceuticals' Non-Current Deffered Revenue rose 327.10% to $457,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $457,000, marking a year-over-year increase of 327.10%. This contributed to the annual value of $457,000 for FY2018, which is 327.10% up from last year.
  • As of Q4 2018, Rocket Pharmaceuticals' Non-Current Deffered Revenue stood at $457,000, which was up 4.34% from $438,000 recorded in Q3 2018.
  • Over the past 5 years, Rocket Pharmaceuticals' Non-Current Deffered Revenue peaked at $598,000 during Q1 2018, and registered a low of $107,000 during Q4 2017.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $457,000 (2018), whereas its average is $422,000.
  • Data for Rocket Pharmaceuticals' Non-Current Deffered Revenue shows a peak YoY soared of 327.10% (in 2018) over the last 5 years.
  • Over the past 2 years, Rocket Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $107,000 in 2017, then skyrocketed by 327.10% to $457,000 in 2018.
  • Its Non-Current Deffered Revenue stands at $457,000 for Q4 2018, versus $438,000 for Q3 2018 and $510,000 for Q2 2018.